CS
MLTX icon

Credit Suisse’s MoonLake Immunotherapeutics MLTX Stock Holding History

Credit Suisse’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$965K Hold
19,204
– – ﹤0.01% 2293
2023
Q4 		$1.16M Buy
19,204
+5,067
+36% +$261K ﹤0.01% 2245
2023
Q3 		$806K Buy
+14,137
New +$780K ﹤0.01% 2422
2022
Q1 		– Sell
-371,849
Closed -$3.68M – 4053
2021
Q4 		$3.68M Buy
+371,849
New +$3.69M ﹤0.01% 2283

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Credit Suisse's MLTX Position: Q1 2024 in Review

Credit Suisse held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2024 at 19,204 shares worth $965K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Credit Suisse first reported a position in MLTX in Q4 2021 and has held it in 4 quarters since. The position peaked at $3.68M in Q4 2021. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Credit Suisse held 19,204 shares of MoonLake Immunotherapeutics worth $965K as of Q1 2024.
  • Credit Suisse left its MoonLake Immunotherapeutics share count unchanged in Q1 2024.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2293 holding.
  • Credit Suisse first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 4 quarters since.
  • Credit Suisse's MoonLake Immunotherapeutics position peaked at $3.68M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.